CKX11 Antibody

What is CSNK1A1 and why is it significant in scientific research?

CSNK1A1 (Casein kinase I isoform alpha, also referred to as CK-I alpha or CK1α) is a serine/threonine protein kinase that functions as a key regulator of multiple signaling pathways, particularly the Wnt/β-catenin pathway. This protein plays a central role in cellular function and has emerged as an attractive target for therapeutic development across various diseases . CSNK1A1 has particular significance in hematological cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and multiple myeloma (MM), where it regulates cellular proliferation and survival . The ability to reliably detect and study this protein is critical for advancing our understanding of disease mechanisms and developing potential therapeutic approaches.

How should I select an appropriate antibody for CSNK1A1 detection?

When selecting a CSNK1A1 antibody, consider these key factors:

• Intended application: Different antibodies perform variably across Western blot, immunoprecipitation, and immunofluorescence applications.

• Target epitope: Choose antibodies targeting different epitopes based on your experimental needs.

• Clonality: Consider whether monoclonal, polyclonal, or recombinant antibodies best suit your research.

• Validation status: Review characterization data comparing wild-type vs. knockout/knockdown cells.

• Renewable source: Prioritize recombinant antibodies for consistent results across experiments.

Reference standardized characterization studies that evaluate antibodies across multiple applications using knockout/knockdown models as negative controls . For instance, in one comprehensive study, ten commercial CSNK1A1 antibodies were systematically evaluated using identical experimental protocols in wild-type and knockdown cell lines .

What cell lines are recommended for positive controls when working with CSNK1A1 antibodies?

Based on systematic evaluation of expression levels, these cell lines show high CSNK1A1 expression and are suitable for positive controls:

HCT 116 shows the highest expression levels and has been successfully used in antibody validation studies . When selecting a cell line, consider both the expression level and the relevance to your specific research context.

How can I validate CSNK1A1 antibody specificity in my experiments?

To validate CSNK1A1 antibody specificity:

• Utilize knockdown/knockout controls: As CSNK1A1 is essential in many cancer cells, siRNA knockdown rather than complete knockout is recommended to maintain cell viability while providing a negative control .

• Compare multiple antibodies: Test several antibodies targeting different epitopes and compare band patterns.

• Include molecular weight markers: Confirm the detected band matches the expected molecular weight of CSNK1A1 (approximately 38 kDa).

• Recombinant protein controls: Include purified CSNK1A1 protein as a positive control when available.

• Cross-validation approach: Validate results using complementary techniques (Western blot, immunofluorescence, etc.).

Most importantly, always include appropriate negative controls, ideally a genetic model where the target is absent or significantly reduced .

What are the optimal conditions for detecting CSNK1A1 by Western blot?

For optimal CSNK1A1 Western blot detection:

• Lysis buffer: Use RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with 1× protease inhibitor cocktail mix .

• Sample preparation:

  • Brief sonication followed by 30-minute incubation on ice

  • Centrifugation at ~110,000 ×g for 15 minutes at 4°C

  • Load equal protein amounts from the supernatants

• Antibody selection: Based on validation studies, select antibodies showing clear differential detection between wild-type and knockdown samples. Several commercially available antibodies have demonstrated high specificity in Western blot applications .

• Blocking conditions: Optimize blocking conditions (typically 5% non-fat dry milk or BSA) to minimize background.

• Incubation parameters: Follow manufacturer's recommendations for primary and secondary antibody dilutions, but be prepared to optimize these parameters for your specific conditions.

Testing multiple antibodies targeting different epitopes can provide more comprehensive and reliable results, especially when studying potential post-translational modifications or isoforms .

How can I successfully use CSNK1A1 antibodies for immunoprecipitation studies?

For successful immunoprecipitation of CSNK1A1:

• Antibody selection: Not all antibodies that perform well in Western blot are suitable for immunoprecipitation. Choose antibodies specifically validated for this application .

• Lysis conditions: Use Pierce IP Lysis Buffer or a similar mild detergent buffer that preserves protein-protein interactions .

• Antibody coupling: Prepare antibody-bead conjugates by adding approximately 2 μg of antibody (for antibodies at known concentration) to protein A (for rabbit antibodies) or protein G (for mouse and sheep antibodies) magnetic beads .

• Validation approach:

  • Analyze equal amounts of starting material, unbound fractions, and immunoprecipitate eluates by SDS-PAGE

  • Detect CSNK1A1 using a well-validated antibody for Western blot

  • Compare results with an isotype control antibody to assess specificity

• Technical considerations:

  • Pre-clear lysates to reduce non-specific binding

  • Include appropriate controls (isotype, no-antibody)

  • Consider crosslinking antibodies to beads for cleaner results

Successful immunoprecipitation can enable studies of CSNK1A1 protein interactions, post-translational modifications, and activity regulation .

What techniques can I use to study CSNK1A1 function in hematological cancers?

To investigate CSNK1A1 function in hematological cancers:

• Inhibitor studies: Utilize specific CK1α inhibitors such as BTX-A51, which has entered Phase I clinical trials for relapsed/refractory AML and high-risk MDS (NCT04243785) . Consider that some compounds (like A-51) may also inhibit additional kinases such as CDK7/CDK9, potentially complicating interpretation of results .

• Genetic approaches:

  • siRNA/shRNA for temporary knockdown

  • CRISPR/Cas9 for genetic ablation (note: complete knockout may affect cell viability)

  • Inducible systems to study time-dependent effects

• Signaling pathway analysis:

  • Study effects on p53 activation and β-catenin regulation

  • Investigate impacts on MYC, MCL1, and MDM2 expression

  • Examine effects on cell cycle progression and apoptosis

• Disease-specific contexts:

  • In del(5q) MDS: Study interactions with lenalidomide, which induces CK1α degradation

  • In MM: Investigate synergy with proteasome inhibitors (bortezomib) and immune modulators (lenalidomide)

  • In AML: Examine effects on hematopoietic stem and progenitor cells

• Functional readouts:

  • Cell viability and proliferation assays

  • Colony formation assays

  • Apoptosis markers

  • Cell differentiation markers

Remember that CK1α may have both cell-intrinsic effects and influence interactions with the microenvironment, requiring comprehensive experimental approaches .

How do I optimize immunofluorescence protocols for CSNK1A1 detection?

For optimal immunofluorescence detection of CSNK1A1:

• Mosaic approach: A powerful validation strategy involves labeling wild-type and knockdown cells with different fluorescent dyes to distinguish cell populations, then imaging them in the same field of view to reduce staining and imaging bias .

• Antibody selection: Choose antibodies specifically validated for immunofluorescence. Not all antibodies that perform well in Western blot will work effectively in this application .

• Fixation optimization:

  • Test different fixation methods (formaldehyde, methanol, acetone)

  • Optimize fixation duration to preserve epitope accessibility

• Signal quantification: Perform quantitative analysis of immunofluorescence intensity across hundreds of cells for each condition to statistically validate specific staining .

• Controls and validation:

  • Include CSNK1A1 knockdown cells as negative controls

  • Compare staining patterns across multiple antibodies

  • Use nuclear counterstains to assess subcellular localization

When interpreting results, consider the known subcellular distribution of CSNK1A1 and compare your findings with published localization patterns .

How can I investigate CSNK1A1's role in the Wnt/β-catenin pathway?

To study CSNK1A1's role in the Wnt/β-catenin pathway:

• Pathway activation monitoring:

  • Assess β-catenin levels and nuclear translocation following CSNK1A1 inhibition or knockdown

  • Measure Wnt target gene expression (e.g., AXIN2, c-MYC, CCND1)

  • Use TOPFlash/FOPFlash reporter assays to quantify canonical Wnt signaling

• Phosphorylation analysis:

  • CSNK1A1 phosphorylates β-catenin at Ser45, which primes it for phosphorylation by GSK3β

  • Use phospho-specific antibodies to monitor these modifications

  • Consider mass spectrometry approaches for comprehensive phosphorylation analysis

• Protein-protein interactions:

  • Co-immunoprecipitation to assess interactions with β-catenin, Axin, APC, and other pathway components

  • Proximity ligation assays for in situ interaction detection

  • FRET/BRET approaches for dynamic interaction studies

• Context-dependent regulation:

  • Compare effects in Wnt-activated versus Wnt-inactive conditions

  • Assess cross-talk with other signaling pathways regulated by CSNK1A1

  • Evaluate effects in different cell types (e.g., hematopoietic versus epithelial cells)

• Disease relevance:

  • Examine correlations between CSNK1A1 expression/activity and Wnt pathway activation in patient samples

  • Explore how mutations in Wnt pathway components affect CSNK1A1 function

This protein plays a central but complex role in Wnt signaling, with context-dependent functions that may vary across cell types and disease states .

How do I interpret conflicting results from different CSNK1A1 antibodies?

When facing conflicting results from different CSNK1A1 antibodies:

• Consider epitope location: Different antibodies target distinct epitopes that may be differentially accessible or modified based on:

  • Protein conformation

  • Post-translational modifications

  • Protein-protein interactions

  • Splice variants

• Evaluate antibody quality: Assess each antibody's validation status:

  • Was it tested in knockout/knockdown systems?

  • Does it show consistent results across applications?

  • Is it a monoclonal, polyclonal, or recombinant antibody?

• Cross-validation approaches:

  • Use multiple techniques (Western blot, IP, IF) to confirm findings

  • Employ orthogonal methods (e.g., mass spectrometry) for ultimate confirmation

  • Validate with genetic approaches (siRNA, CRISPR)

• Systematic comparison:

  • Test antibodies side-by-side under identical conditions

  • Document differences in band patterns, intensity, and background

  • Consult published antibody characterization studies

Remember that even high-quality antibodies may perform differently across applications and experimental conditions. When possible, prioritize recombinant antibodies for improved reproducibility .

What controls should I include when studying CSNK1A1 in primary patient samples?

When studying CSNK1A1 in primary patient samples:

• Essential controls:

  • Positive cell line controls with known CSNK1A1 expression (e.g., HCT 116)

  • Loading controls appropriate for the sample type

  • Isotype controls for immunostaining applications

  • Multiple antibodies targeting different epitopes when possible

• Sample-specific considerations:

  • For hematological samples: Include normal peripheral blood or bone marrow samples from healthy donors

  • For tissue samples: Include adjacent normal tissue

  • Consider cell type heterogeneity in bulk samples

• Technical validation:

  • Perform antibody titration to determine optimal concentration

  • Include non-specific binding controls

  • For immunohistochemistry: Use both positive and negative clinical samples with known status

• Disease-specific controls:

  • For MDS/AML studies: Include samples with and without del(5q)

  • For multiple myeloma: Compare plasma cells to normal B cells

  • Consider genetic background and treatment history

• Data interpretation:

  • Account for patient-to-patient variability

  • Consider clinical parameters when interpreting results

  • Validate key findings using orthogonal techniques

These controls are essential for accurate interpretation of CSNK1A1 expression or activity in clinical samples, particularly given the heterogeneity inherent to patient material.

How can I assess potential off-target effects when using CK1 inhibitors in my research?

To assess off-target effects of CK1 inhibitors:

• Kinase profiling:

  • Review published kinase selectivity data for your inhibitor

  • For compounds like BTX-A51, note that they inhibit multiple kinases including CK1δ, CK1ε, CDK7, CDK9, and kinases from JNK, DYRK, and JNK families

  • Consider custom kinase profiling if selectivity data is limited

• Validation approaches:

  • Compare multiple structurally distinct CK1 inhibitors

  • Correlate pharmacological inhibition with genetic knockdown effects

  • Use rescue experiments with inhibitor-resistant CK1α mutants

• Pathway analysis:

  • Monitor markers of pathways known to be affected by off-target kinases

  • For BTX-A51, assess super-enhancer regulation (CDK7/9 inhibition) and MYC/MCL1/MDM2 expression

  • Use phospho-proteomics to evaluate broader signaling effects

• Isoform specificity:

  • Consider redundancy between CK1 isoforms (particularly CK1δ and CK1ε)

  • Note that pan-CK1 or dual CK1δ/ε inhibitors may have different biological effects than CK1α-specific compounds

  • Use isoform-specific genetic modulation for comparison

• Concentration-response relationships:

  • Establish dose-response curves for on-target versus off-target effects

  • Determine the therapeutic window for specific CK1α inhibition

  • Consider time-dependent effects that may differentiate primary and secondary responses

Remember that while off-target effects complicate mechanistic interpretation, they may contribute to the therapeutic potential of these compounds in certain contexts .

How can I design experiments to investigate CSNK1A1's immunomodulatory effects?

To study CSNK1A1's immunomodulatory functions:

• T cell function assays:

  • Investigate immunological synapse formation, which requires CK1δ

  • Assess Treg protection effects with CK1ε inhibition

  • Measure T cell activation markers following CK1 modulation

• Inflammatory pathway analysis:

  • Monitor non-canonical Wnt signaling, which mediates inflammatory responses

  • Measure WNT-5A levels, a biomarker associated with inflammatory conditions

  • Assess cytokine production and secretion

• Disease models:

  • Consider models of inflammatory conditions where CK1 has been implicated:

    • Rheumatoid arthritis

    • Osteoarthritis

    • Psoriasis vulgaris

    • SARS-CoV-2 infection

  • Evaluate effects of CK1 inhibition on disease progression

• Cell-cell interaction studies:

  • Design co-culture experiments with immune cells and target cells

  • Investigate effects on immune cell recruitment and function

  • Assess changes in the tumor microenvironment

• Translational approaches:

  • Correlate CSNK1A1 expression/activity with immune infiltration in patient samples

  • Evaluate combination approaches with immune modulators

  • Consider differential effects across immune cell subsets

These experiments should account for the context-dependent roles of CSNK1A1 in immune regulation and the potential differences between acute and chronic inhibition effects .

What are the latest approaches for developing isoform-selective CK1 inhibitors for research use?

Recent advances in developing isoform-selective CK1 inhibitors include:

• Structure-guided design:

  • Leveraging X-ray crystal structures of CK1 isoforms

  • Targeting non-conserved regions outside the ATP binding pocket

  • Developing allosteric inhibitors with enhanced selectivity

• Selectivity considerations:

  • Current challenges include distinguishing between CK1α and other isoforms (δ, ε)

  • Many inhibitors like BTX-A51 target multiple CK1 family members

  • Pan-CK1 or CK1δ/ε dual inhibitors may have higher on-target toxicity than isoform-specific compounds

• Therapeutic window assessment:

  • Some pan-CK1 or CK1δ/ε dual inhibitors appear well-tolerated in preclinical models

  • Clinical data with umbralisib suggests CK1ε inhibition is tolerated in patients

  • Tissue-specific effects must be considered (e.g., intestinal stem cell depletion occurred only with combined CK1δ/ε inhibition)

• Degrader technology:

  • Proteolysis-targeting chimeras (PROTACs) offer a novel approach for selective CK1α degradation

  • Lenalidomide provides a model for CK1α-targeted degradation via CRL4CRBN complex

  • Developing selective degraders may provide functional selectivity beyond kinase inhibition

• Combination strategies:

  • In multiple myeloma, CK1α inhibition synergizes with proteasome inhibitors and immune modulators

  • Understanding pathway interactions can guide rational combination approaches

  • CK1α inhibition can affect multiple mechanisms including autophagy regulation, MYC expression, and p53 activation

Researchers should remain aware of the polypharmacology of current CK1 inhibitors while pursuing more selective tools for discrete modulation of individual isoforms .